
AbbVie Inc. (NYSE: ABBV) Stock Competitors & Peer Comparison
See ABBV's competitors and their performance on the NYSE and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - General Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for ABBV and its NYSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ABBV | $283.54 | -0.86% | 501.2B | 27.82 | $10.19 | +2.45% |
| LLY | $1,351.12 | -2.29% | 1.3T | 42.91 | $31.49 | +0.51% |
| JNJ | $267.14 | -2.04% | 643.2B | 24.90 | $10.73 | +1.99% |
| MRK | $132.81 | -3.61% | 327.3B | 41.36 | $3.21 | +2.58% |
| NVS | $151.22 | -2.57% | 285.6B | 17.40 | $8.69 | +3.14% |
| AZN | $175.41 | -1.87% | 272.1B | 18.94 | $9.26 | +1.85% |
| AMGN | $438.82 | -1.14% | 237.4B | 19.62 | $22.37 | +2.26% |
| GILD | $166.53 | -1.45% | 206.6B | -427.00 | -$0.39 | +1.95% |
| NVO | $38.87 | -1.42% | 171.4B | 9.68 | $4.02 | +4.64% |
| PFE | $27.54 | -1.85% | 157.2B | 9.04 | $3.05 | +6.25% |
Stock Comparison
Eli Lilly and Company (NYSE: LLY)
ABBV vs LLY Comparison November 2026
AbbVie Inc. (NYSE: ABBV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBV stands at 501.2B. In comparison, LLY has a market cap of 1.3T. Regarding current trading prices, ABBV is priced at $283.54 on the NYSE, while LLY trades at $1,351.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBV currently has a P/E ratio of 27.82, whereas LLY's P/E ratio is 42.91. In terms of profitability, ABBV's ROE is -2.02%, compared to LLY's ROE of +0.84%. Regarding short-term risk, ABBV is less volatile compared to LLY. This indicates lower risk in terms of short-term price fluctuations for ABBV.Check LLY's competition here
Johnson & Johnson (NYSE: JNJ)
ABBV vs JNJ Comparison November 2026
AbbVie Inc. (NYSE: ABBV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBV stands at 501.2B. In comparison, JNJ has a market cap of 643.2B. Regarding current trading prices, ABBV is priced at $283.54 on the NYSE, while JNJ trades at $267.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBV currently has a P/E ratio of 27.82, whereas JNJ's P/E ratio is 24.90. In terms of profitability, ABBV's ROE is -2.02%, compared to JNJ's ROE of +0.20%. Regarding short-term risk, ABBV is less volatile compared to JNJ. This indicates lower risk in terms of short-term price fluctuations for ABBV.Check JNJ's competition here
Merck & Co., Inc. (NYSE: MRK)
ABBV vs MRK Comparison November 2026
AbbVie Inc. (NYSE: ABBV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBV stands at 501.2B. In comparison, MRK has a market cap of 327.3B. Regarding current trading prices, ABBV is priced at $283.54 on the NYSE, while MRK trades at $132.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBV currently has a P/E ratio of 27.82, whereas MRK's P/E ratio is 41.36. In terms of profitability, ABBV's ROE is -2.02%, compared to MRK's ROE of +0.05%. Regarding short-term risk, ABBV is less volatile compared to MRK. This indicates lower risk in terms of short-term price fluctuations for ABBV.Check MRK's competition here
Novartis AG (NYSE: NVS)
ABBV vs NVS Comparison November 2026
AbbVie Inc. (NYSE: ABBV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBV stands at 501.2B. In comparison, NVS has a market cap of 285.6B. Regarding current trading prices, ABBV is priced at $283.54 on the NYSE, while NVS trades at $151.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBV currently has a P/E ratio of 27.82, whereas NVS's P/E ratio is 17.40. In terms of profitability, ABBV's ROE is -2.02%, compared to NVS's ROE of +0.25%. Regarding short-term risk, ABBV is more volatile compared to NVS. This indicates higher risk in terms of short-term price fluctuations for ABBV.Check NVS's competition here
AstraZeneca PLC (NYSE: AZN)
ABBV vs AZN Comparison November 2026
AbbVie Inc. (NYSE: ABBV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBV stands at 501.2B. In comparison, AZN has a market cap of 272.1B. Regarding current trading prices, ABBV is priced at $283.54 on the NYSE, while AZN trades at $175.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBV currently has a P/E ratio of 27.82, whereas AZN's P/E ratio is 18.94. In terms of profitability, ABBV's ROE is -2.02%, compared to AZN's ROE of +0.22%. Regarding short-term risk, ABBV is less volatile compared to AZN. This indicates lower risk in terms of short-term price fluctuations for ABBV.Check AZN's competition here
Amgen Inc. (NASDAQ: AMGN)
ABBV vs AMGN Comparison November 2026
AbbVie Inc. (NYSE: ABBV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBV stands at 501.2B. In comparison, AMGN has a market cap of 237.4B. Regarding current trading prices, ABBV is priced at $283.54 on the NYSE, while AMGN trades at $438.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBV currently has a P/E ratio of 27.82, whereas AMGN's P/E ratio is 19.62. In terms of profitability, ABBV's ROE is -2.02%, compared to AMGN's ROE of +0.86%. Regarding short-term risk, ABBV is more volatile compared to AMGN. This indicates higher risk in terms of short-term price fluctuations for ABBV.Check AMGN's competition here
Gilead Sciences, Inc. (NASDAQ: GILD)
ABBV vs GILD Comparison November 2026
AbbVie Inc. (NYSE: ABBV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBV stands at 501.2B. In comparison, GILD has a market cap of 206.6B. Regarding current trading prices, ABBV is priced at $283.54 on the NYSE, while GILD trades at $166.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBV currently has a P/E ratio of 27.82, whereas GILD's P/E ratio is -427.00. In terms of profitability, ABBV's ROE is -2.02%, compared to GILD's ROE of -0.22%. Regarding short-term risk, ABBV is less volatile compared to GILD. This indicates lower risk in terms of short-term price fluctuations for ABBV.Check GILD's competition here
Novo Nordisk A/S (NYSE: NVO)
ABBV vs NVO Comparison November 2026
AbbVie Inc. (NYSE: ABBV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBV stands at 501.2B. In comparison, NVO has a market cap of 171.4B. Regarding current trading prices, ABBV is priced at $283.54 on the NYSE, while NVO trades at $38.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBV currently has a P/E ratio of 27.82, whereas NVO's P/E ratio is 9.68. In terms of profitability, ABBV's ROE is -2.02%, compared to NVO's ROE of +0.54%. Regarding short-term risk, ABBV is less volatile compared to NVO. This indicates lower risk in terms of short-term price fluctuations for ABBV.Check NVO's competition here
Pfizer Inc. (NYSE: PFE)
ABBV vs PFE Comparison November 2026
AbbVie Inc. (NYSE: ABBV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBV stands at 501.2B. In comparison, PFE has a market cap of 157.2B. Regarding current trading prices, ABBV is priced at $283.54 on the NYSE, while PFE trades at $27.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBV currently has a P/E ratio of 27.82, whereas PFE's P/E ratio is 9.04. In terms of profitability, ABBV's ROE is -2.02%, compared to PFE's ROE of +0.05%. Regarding short-term risk, ABBV is more volatile compared to PFE. This indicates higher risk in terms of short-term price fluctuations for ABBV.Check PFE's competition here
Bristol-Myers Squibb Company (NYSE: BMY)
ABBV vs BMY Comparison November 2026
AbbVie Inc. (NYSE: ABBV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBV stands at 501.2B. In comparison, BMY has a market cap of 119.2B. Regarding current trading prices, ABBV is priced at $283.54 on the NYSE, while BMY trades at $58.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBV currently has a P/E ratio of 27.82, whereas BMY's P/E ratio is 9.84. In terms of profitability, ABBV's ROE is -2.02%, compared to BMY's ROE of +0.44%. Regarding short-term risk, ABBV is less volatile compared to BMY. This indicates lower risk in terms of short-term price fluctuations for ABBV.Check BMY's competition here
Sanofi (NASDAQ: SNY)
ABBV vs SNY Comparison November 2026
AbbVie Inc. (NYSE: ABBV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBV stands at 501.2B. In comparison, SNY has a market cap of 112.9B. Regarding current trading prices, ABBV is priced at $283.54 on the NYSE, while SNY trades at $46.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBV currently has a P/E ratio of 27.82, whereas SNY's P/E ratio is 10.03. In terms of profitability, ABBV's ROE is -2.02%, compared to SNY's ROE of +0.06%. Regarding short-term risk, ABBV is less volatile compared to SNY. This indicates lower risk in terms of short-term price fluctuations for ABBV.Check SNY's competition here
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI)
ABBV vs CELG-RI Comparison November 2026
AbbVie Inc. (NYSE: ABBV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBV stands at 501.2B. In comparison, CELG-RI has a market cap of 106.6B. Regarding current trading prices, ABBV is priced at $283.54 on the NYSE, while CELG-RI trades at $0.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBV currently has a P/E ratio of 27.82, whereas CELG-RI's P/E ratio is N/A. In terms of profitability, ABBV's ROE is -2.02%, compared to CELG-RI's ROE of +0.44%. Regarding short-term risk, ABBV is less volatile compared to CELG-RI. This indicates lower risk in terms of short-term price fluctuations for ABBV.Check CELG-RI's competition here
GSK plc (NYSE: GSK)
ABBV vs GSK Comparison November 2026
AbbVie Inc. (NYSE: ABBV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBV stands at 501.2B. In comparison, GSK has a market cap of 95.9B. Regarding current trading prices, ABBV is priced at $283.54 on the NYSE, while GSK trades at $47.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBV currently has a P/E ratio of 27.82, whereas GSK's P/E ratio is 10.33. In terms of profitability, ABBV's ROE is -2.02%, compared to GSK's ROE of +0.23%. Regarding short-term risk, ABBV is more volatile compared to GSK. This indicates higher risk in terms of short-term price fluctuations for ABBV.Check GSK's competition here
Biogen Inc. (NASDAQ: BIIB)
ABBV vs BIIB Comparison November 2026
AbbVie Inc. (NYSE: ABBV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBV stands at 501.2B. In comparison, BIIB has a market cap of 36.5B. Regarding current trading prices, ABBV is priced at $283.54 on the NYSE, while BIIB trades at $247.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBV currently has a P/E ratio of 27.82, whereas BIIB's P/E ratio is 15.60. In terms of profitability, ABBV's ROE is -2.02%, compared to BIIB's ROE of +0.02%. Regarding short-term risk, ABBV is less volatile compared to BIIB. This indicates lower risk in terms of short-term price fluctuations for ABBV.Check BIIB's competition here
Horizon Therapeutics Public Limited Company (NASDAQ: HZNP)
ABBV vs HZNP Comparison November 2026
AbbVie Inc. (NYSE: ABBV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBV stands at 501.2B. In comparison, HZNP has a market cap of 26.6B. Regarding current trading prices, ABBV is priced at $283.54 on the NYSE, while HZNP trades at $116.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBV currently has a P/E ratio of 27.82, whereas HZNP's P/E ratio is 61.86. In terms of profitability, ABBV's ROE is -2.02%, compared to HZNP's ROE of +0.11%. Regarding short-term risk, ABBV is more volatile compared to HZNP. This indicates higher risk in terms of short-term price fluctuations for ABBV.Check HZNP's competition here
Grifols, S.A. (NASDAQ: GRFS)
ABBV vs GRFS Comparison November 2026
AbbVie Inc. (NYSE: ABBV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBV stands at 501.2B. In comparison, GRFS has a market cap of 6.9B. Regarding current trading prices, ABBV is priced at $283.54 on the NYSE, while GRFS trades at $8.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBV currently has a P/E ratio of 27.82, whereas GRFS's P/E ratio is 9.42. In terms of profitability, ABBV's ROE is -2.02%, compared to GRFS's ROE of +0.09%. Regarding short-term risk, ABBV is more volatile compared to GRFS. This indicates higher risk in terms of short-term price fluctuations for ABBV.Check GRFS's competition here
Organon & Co. (NYSE: OGN)
ABBV vs OGN Comparison November 2026
AbbVie Inc. (NYSE: ABBV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBV stands at 501.2B. In comparison, OGN has a market cap of 3.7B. Regarding current trading prices, ABBV is priced at $283.54 on the NYSE, while OGN trades at $13.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBV currently has a P/E ratio of 27.82, whereas OGN's P/E ratio is 4.15. In terms of profitability, ABBV's ROE is -2.02%, compared to OGN's ROE of +0.22%. Regarding short-term risk, ABBV is more volatile compared to OGN. This indicates higher risk in terms of short-term price fluctuations for ABBV.Check OGN's competition here
Amarin Corporation plc (NASDAQ: AMRN)
ABBV vs AMRN Comparison November 2026
AbbVie Inc. (NYSE: ABBV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBV stands at 501.2B. In comparison, AMRN has a market cap of 237.2M. Regarding current trading prices, ABBV is priced at $283.54 on the NYSE, while AMRN trades at $11.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBV currently has a P/E ratio of 27.82, whereas AMRN's P/E ratio is -112.50. In terms of profitability, ABBV's ROE is -2.02%, compared to AMRN's ROE of -0.04%. Regarding short-term risk, ABBV is more volatile compared to AMRN. This indicates higher risk in terms of short-term price fluctuations for ABBV.Check AMRN's competition here
MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA)
ABBV vs MIRA Comparison November 2026
AbbVie Inc. (NYSE: ABBV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBV stands at 501.2B. In comparison, MIRA has a market cap of 15.6M. Regarding current trading prices, ABBV is priced at $283.54 on the NYSE, while MIRA trades at $0.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBV currently has a P/E ratio of 27.82, whereas MIRA's P/E ratio is -0.26. In terms of profitability, ABBV's ROE is -2.02%, compared to MIRA's ROE of -1.12%. Regarding short-term risk, ABBV is less volatile compared to MIRA. This indicates lower risk in terms of short-term price fluctuations for ABBV.Check MIRA's competition here
Scilex Holding Company (NASDAQ: SCLXW)
ABBV vs SCLXW Comparison November 2026
AbbVie Inc. (NYSE: ABBV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBV stands at 501.2B. In comparison, SCLXW has a market cap of 14.6M. Regarding current trading prices, ABBV is priced at $283.54 on the NYSE, while SCLXW trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBV currently has a P/E ratio of 27.82, whereas SCLXW's P/E ratio is N/A. In terms of profitability, ABBV's ROE is -2.02%, compared to SCLXW's ROE of +1.90%. Regarding short-term risk, ABBV is more volatile compared to SCLXW. This indicates higher risk in terms of short-term price fluctuations for ABBV.Check SCLXW's competition here
Scilex Holding Company (NASDAQ: SCLX)
ABBV vs SCLX Comparison November 2026
AbbVie Inc. (NYSE: ABBV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBV stands at 501.2B. In comparison, SCLX has a market cap of 4.5M. Regarding current trading prices, ABBV is priced at $283.54 on the NYSE, while SCLX trades at $0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBV currently has a P/E ratio of 27.82, whereas SCLX's P/E ratio is -0.02. In terms of profitability, ABBV's ROE is -2.02%, compared to SCLX's ROE of +1.90%. Regarding short-term risk, ABBV is less volatile compared to SCLX. This indicates lower risk in terms of short-term price fluctuations for ABBV.Check SCLX's competition here
BioDelivery Sciences Intl, Inc. Wrrt (NASDAQ: BDSIW)
ABBV vs BDSIW Comparison November 2026
AbbVie Inc. (NYSE: ABBV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBV stands at 501.2B. In comparison, BDSIW has a market cap of 0. Regarding current trading prices, ABBV is priced at $283.54 on the NYSE, while BDSIW trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBV currently has a P/E ratio of 27.82, whereas BDSIW's P/E ratio is -0.43. In terms of profitability, ABBV's ROE is -2.02%, compared to BDSIW's ROE of -0.31%. Regarding short-term risk, ABBV is less volatile compared to BDSIW. This indicates lower risk in terms of short-term price fluctuations for ABBV.Check BDSIW's competition here
Clarus Therapeutics Holdings, Inc. (NASDAQ: CRXT)
ABBV vs CRXT Comparison November 2026
AbbVie Inc. (NYSE: ABBV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBV stands at 501.2B. In comparison, CRXT has a market cap of 0. Regarding current trading prices, ABBV is priced at $283.54 on the NYSE, while CRXT trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBV currently has a P/E ratio of 27.82, whereas CRXT's P/E ratio is -0.02. In terms of profitability, ABBV's ROE is -2.02%, compared to CRXT's ROE of -4.63%. Regarding short-term risk, ABBV is less volatile compared to CRXT. This indicates lower risk in terms of short-term price fluctuations for ABBV.Check CRXT's competition here